| Literature DB >> 20418879 |
Frank J Dekker1, Oliver Rocks, Nachiket Vartak, Sascha Menninger, Christian Hedberg, Rengarajan Balamurugan, Stefan Wetzel, Steffen Renner, Marc Gerauer, Beate Schölermann, Marion Rusch, John W Kramer, Daniel Rauh, Geoffrey W Coates, Luc Brunsveld, Philippe I H Bastiaens, Herbert Waldmann.
Abstract
Cycles of depalmitoylation and repalmitoylation critically control the steady-state localization and function of various peripheral membrane proteins, such as Ras proto-oncogene products. Interference with acylation using small molecules is a strategy to modulate cellular localization--and thereby unregulated signaling--caused by palmitoylated Ras proteins. We present the knowledge-based development and characterization of a potent inhibitor of acyl protein thioesterase 1 (APT1), a bona fide depalmitoylating enzyme that is, so far, poorly characterized in cells. The inhibitor, palmostatin B, perturbs the cellular acylation cycle at the level of depalmitoylation and thereby causes a loss of the precise steady-state localization of palmitoylated Ras. As a consequence, palmostatin B induces partial phenotypic reversion in oncogenic HRasG12V-transformed fibroblasts. We identify APT1 as one of the thioesterases in the acylation cycle and show that this protein is a cellular target of the inhibitor.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20418879 DOI: 10.1038/nchembio.362
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040